Management of Blood Cholesterol

https://jamanetwork.com/journals/jama/fullarticle/2724002?guestAccessKey=7cbd7342-c4e0-45e7-ba5b-4a0f257cb546&utm_source=linkedin_company&utm_medium=social_jama&utm_term=2161228708&utm_content=followers-article_engagement-figure-tfl&utm_campaign=article_alert&linkId=64089723

Pharmacologically lowering low-density lipoprotein cholesterol (LDL-C) consistently reduces ASCVD events (myocardial infarction, stroke, and cardiovascular death), and the principle that lower LDL-C is better was reaffirmed by trials that added ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statin therapy.^1,2 The 2013 guideline removed specific LDL-C treatment targets, but high-quality trials since offered the opportunity to reintroduce such goals based on risk gradations..............